Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 3/20 | 0.52 |
| ▸ | HTR1B | P28222 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | HTR1F | P30939 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30496473 | 1.00 | QDPR (0.52) | QDPRHTR1DHTR1BDRD2APP | |
| SCHEMBL10036163 | 0.92 | HTR1D (0.49) | QDPRHTR1DHTR1BDRD2APP | |
| SCHEMBL7029357 | 0.88 | QDPR (0.52) | QDPRHTR1DHTR1BDRD2APP | |
| SCHEMBL2570589 | 0.87 | MAPT (0.48) | GAAMAPTTSHRMAPK1HTT | |
| SCHEMBL4562943 | 0.84 | HTR1D (0.49) | QDPRHTR1DHTR1BDRD2GAA | |
| SCHEMBL30020108 | 0.84 | HTR1D (0.49) | QDPRHTR1DHTR1BDRD2MAPT | |
| SCHEMBL20899571 | 0.84 | MEN1 (0.39) | QDPRHTR1DHTR1BDRD2GAA | |
| SCHEMBL30962643 | 0.84 | HTR1D (0.49) | QDPRHTR1DHTR1BDRD2GAA | |
| SCHEMBL30868519 | 0.83 | HTR2A (0.54) | GAAMAPTTSHRMAPK1HTT | |
| SCHEMBL10036181 | 0.83 | DRD2 (0.51) | DRD2MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078126-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4642767-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | Acrivon Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12448364-B2 | 2, 4-diaminopyrimidine derivative and application thereof | SHANGHAI ZHEYE BIOTECHNOLOGY CO., LTD. (CN) | 2025-10-21 | — | — | US | disclosed |
| US-12398145-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE BROAD INSTITUTE, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12121521-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | THE GENERAL HOSPITAL CORPORATION (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240245695-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2024-07-25 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024145505-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | ACRIVON THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-11878019-B2 | Uses of pyrimidopyrimidinones as SIK inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2024-01-23 | — | — | US | disclosed |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| WO-2012053606-A1 | ARYLAMINOHETEROCYCLIC CARBOXAMIDE COMPOUND | アステラス製薬株式会社 (JP) | 2012-04-26 | — | — | WO | disclosed |
| EP-2428508-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121521-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | SOST, CSF1R, SIK2 | QDPR 4306/4885HTR1D 4439/4885HTR1B 4466/4885 |
| US-20140371196-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | QDPR 986/4885HTR1D 3635/4885HTR1B 3677/4885 |
| US-20260078126-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK2, SBK3, SIK3 | QDPR 4510/4885HTR1D 3757/4885HTR1B 1857/4885 |
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | QDPR 1818/4885HTR1D 1845/4885HTR1B 1829/4885 |
| US-12398145-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | QDPR 4720/4885HTR1D 3345/4885HTR1B 3230/4885 |
| US-12448364-B2 | 2, 4-diaminopyrimidine derivative and application thereof | ALK, DPYD, ABL2 | QDPR 112/4885HTR1D 2211/4885HTR1B 2008/4885 |
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | QDPR 986/4885HTR1D 3635/4885HTR1B 3677/4885 |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | QDPR 3742/4885HTR1D 4471/4885HTR1B 4632/4885 |
| US-11878019-B2 | Uses of pyrimidopyrimidinones as SIK inhibitors | SIK2, SIK1, SIK3 | QDPR 1550/4885HTR1D 4577/4885HTR1B 4297/4885 |
| US-20240245695-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | QDPR 1550/4885HTR1D 4577/4885HTR1B 4297/4885 |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | QDPR 4720/4885HTR1D 3345/4885HTR1B 3230/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | QDPR 807/4885HTR1D 3024/4885HTR1B 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.